Introduction
Hypomagnesaemia with secondary hypocalcaemia (HSH) is a rare autosomal recessive disease caused by mutation in a gene located on chromosome 9q22 called TRPM6 gene 1 . We report a child with HSH presenting with intractable seizures which were controlled by giving magnesium.
Case report
A 9 month old boy born of a consanguineous union presented with multiple episodes of generalized tonic clonic convulsions for one month. He was treated with intravenous calcium gluconate and oral calcium supplements for hypocalcaemia [serum calcium 3.9mg/dl, serum phosphorous 9.5mg/dl, simultaneous parathyroid hormone (PTH) level 15.2pg/ml (normal 12-95)] before referring to our hospital. He was also given intramuscular magnesium sulphate for five days without documenting a serum magnesium level. In spite of this treatment the patient kept on having convulsions.
The physical examination was normal. Investigations at our hospital revealed high serum phosphorous (10.8mg/dl), normal alkaline phosphatase (257IU/l) and PTH level inappropriately low (19.4pg/ml) for hypocalcaemia (serum calcium 7.2mg/dl). Serum electrolytes, blood gas analysis, serum 25 hydroxyvitaminD 3 level and urine calcium/creatinine ratio were normal. Serum magnesium level on admission was 3.2mg/dl (normal 1.8-2.4). With a provisional diagnosis of hypoparathyroidism, patient was treated with calcitriol and oral calcium of 0.5µg and 100mg/kg/day which was gradually increased to 2µg and 115mg/kg/day respectively because of persistent hypocalcaemia and intermittent seizures. We then repeated the serum magnesium levels, 22 and 25 days after the initial magnesium report and these were 2mg/dl and 1.4mg/dl (low). Fractional excretion of magnesium (FeMg ++ ) was 11.2% (normal up to 4%). A diagnosis of hypomagnesaemia due to renal magnesium wasting was made. Patient was treated with intramuscular magnesium initially and then with oral magnesium carbonate at 40mg/kg/day after which the serum calcium level normalized (serum calcium 9.1 mg/dl). Calcitriol and calcium were then tapered and stopped. Patient did not experience any further episodes of convulsions. On follow up, serum calcium and magnesium levels were done and found to be low or low normal, on an oral magnesium dose ranging from 25-80mg/kg/day. A diagnosis of HSH was suspected and a mutation analysis was performed on blood. Genomic DNA was isolated. The gene encoding TRPM6 was amplified by PCR and the purified product sequenced by automated DNA sequencer. There was a missense mutation at p.T2L at exon 1 and silent mutation at exon 8F (p.G313G), 16F (p.A619A), 19F (p.Q809Q). The patient is now 3 ½ years old and has normal growth and milestones.
Discussion
HSH, first described by Paunier et al in 1968 is characterised by extremely low levels of serum magnesium accompanied by hypocalcaemia. Hypocalcaemia results from an inhibition of PTH synthesis, its release from parathyroid gland and target organ resistance to PTH 2 . It typically manifests during the first months of life with convulsions, muscle spasms or tetany. Relief of symptoms is achieved by administration of intravenous or intramuscular magnesium followed by life-long treatment with high-dose oral magnesium 3 . If an early diagnosis cannot be made or the treatment is started late, these convulsions can be fatal or may result in neurological sequelae 3 . In the present patient, there was a consanguineous marriage. However the parents had normal magnesium and calcium levels. Our patient, who presented with recurrent and prolonged seizures, was initially diagnosed with primary hypocalcaemia and was treated as such. Similar to most reported cases in the literature 4 , the failure to respond to calcium treatment led to the consideration of magnesium deficiency. After admission our patient had hypocalcaemic convulsions in spite of slightly high serum magnesium level, possibly due to empiric intramuscular magnesium treatment given by the referring physician. Hypocalcaemia may be due to intracellular magnesium depletion, where the major physiologic role of magnesium occurs as there is slow equilibrium between the serum and intracellular magnesium after treating with magnesium 5 . Mean oral magnesium requirement in one multicentre study 3 done on HSH patients was found to be 0.93mmol/kg/day (22.8mg/kg/day) with a range of 0.41-3.9mmol/kg/day (10-96mg/kg/day).Serum magnesium usually fails to reach normal values under oral substitution therapy 3 , as seen in our patient. The main side effect of oral magnesium supplementation is diarrhoea which may require additional intramuscular injections.
TRPM6 gene encodes the TRPM6 protein which belongs to the melastatic related group of a large family of transient receptor potential (TRP) cation channels. It plays an important role in a wide variety of physiological processes, ranging from thermal, tactile, taste to transepithelial Ca ++ and Mg ++ transport 6 . Electrophysiological analysis and expression studies have demonstrated that TRPM6 confines a Mg ++ -permeable channel, which is specifically localised to the apical membrane of Mg ++ -reabsorbing tubules in the kidney (DCT) and the brush border membrane of the Mg ++ absorptive cells in the small intestine 7 . Majority of mutations found in HSH patients introduce stop codons, deletions of exons and frameshifts or affect splice sites, thus resulting in a complete loss of function of TRPM6 protein 3 . These cause the combination of impaired gut reabsorption of magnesium and renal wasting in HSH. In our patient FeMg ++ was high (renal wasting). However stool excretion of magnesium could not be done.
We report this case to sensitise the clinician towards this rare disease, since any delay in diagnosis may cause adverse neurodevelopmental outcome and sometimes may be fatal, the early treatment being very important for prognosis.
